Future role of radiotherapy as a component of treatment in biliopancreatic cancers

Leonard L. Gunderson, Michael Haddock, P. Burch, D. Nagorney, M. L. Foo, T. Todoroki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

For resected and unresectable pancreas cancers, data will be summarized from both adjuvant and locally unresectable pancreas cancer series (EBRT ± IOERT) to demonstrate the justification of continuing to utilize chemo- irradiation as a component of treatment. The resultant improvements in local control with combined modality treatment, however, achieve only minimal improvements in survival in view of the high incidence of abdominal relapse (liver and peritoneal). Further improvement in survival may necessitate regional approaches for chemotherapy or may await advances in gene therapy. For locally unresectable and resected but residual bile duct malignancies, chemoirradiation appears to enhance tumor control and survival. Dose intensification of both modalities may be useful in improving disease control and survival. After chemoirradiation, the addition of liver transplant, in carefully selected patients who are unresectable with standard resection, may further enhance disease control and survival over what would be expected with either approach in isolation.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume10
Issue numberSUPPL. 4
StatePublished - 1999

Fingerprint

Radiotherapy
Survival
Neoplasms
Pancreatic Neoplasms
Therapeutics
Liver
Bile Ducts
Genetic Therapy
Transplants
Recurrence
Drug Therapy
Incidence

Keywords

  • Biliary cancer
  • Chemo-irradiation
  • Pancreas cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gunderson, L. L., Haddock, M., Burch, P., Nagorney, D., Foo, M. L., & Todoroki, T. (1999). Future role of radiotherapy as a component of treatment in biliopancreatic cancers. Annals of Oncology, 10(SUPPL. 4).

Future role of radiotherapy as a component of treatment in biliopancreatic cancers. / Gunderson, Leonard L.; Haddock, Michael; Burch, P.; Nagorney, D.; Foo, M. L.; Todoroki, T.

In: Annals of Oncology, Vol. 10, No. SUPPL. 4, 1999.

Research output: Contribution to journalArticle

Gunderson, LL, Haddock, M, Burch, P, Nagorney, D, Foo, ML & Todoroki, T 1999, 'Future role of radiotherapy as a component of treatment in biliopancreatic cancers', Annals of Oncology, vol. 10, no. SUPPL. 4.
Gunderson LL, Haddock M, Burch P, Nagorney D, Foo ML, Todoroki T. Future role of radiotherapy as a component of treatment in biliopancreatic cancers. Annals of Oncology. 1999;10(SUPPL. 4).
Gunderson, Leonard L. ; Haddock, Michael ; Burch, P. ; Nagorney, D. ; Foo, M. L. ; Todoroki, T. / Future role of radiotherapy as a component of treatment in biliopancreatic cancers. In: Annals of Oncology. 1999 ; Vol. 10, No. SUPPL. 4.
@article{927c4642765b41cabbf490b0a22f7edb,
title = "Future role of radiotherapy as a component of treatment in biliopancreatic cancers",
abstract = "For resected and unresectable pancreas cancers, data will be summarized from both adjuvant and locally unresectable pancreas cancer series (EBRT ± IOERT) to demonstrate the justification of continuing to utilize chemo- irradiation as a component of treatment. The resultant improvements in local control with combined modality treatment, however, achieve only minimal improvements in survival in view of the high incidence of abdominal relapse (liver and peritoneal). Further improvement in survival may necessitate regional approaches for chemotherapy or may await advances in gene therapy. For locally unresectable and resected but residual bile duct malignancies, chemoirradiation appears to enhance tumor control and survival. Dose intensification of both modalities may be useful in improving disease control and survival. After chemoirradiation, the addition of liver transplant, in carefully selected patients who are unresectable with standard resection, may further enhance disease control and survival over what would be expected with either approach in isolation.",
keywords = "Biliary cancer, Chemo-irradiation, Pancreas cancer",
author = "Gunderson, {Leonard L.} and Michael Haddock and P. Burch and D. Nagorney and Foo, {M. L.} and T. Todoroki",
year = "1999",
language = "English (US)",
volume = "10",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Future role of radiotherapy as a component of treatment in biliopancreatic cancers

AU - Gunderson, Leonard L.

AU - Haddock, Michael

AU - Burch, P.

AU - Nagorney, D.

AU - Foo, M. L.

AU - Todoroki, T.

PY - 1999

Y1 - 1999

N2 - For resected and unresectable pancreas cancers, data will be summarized from both adjuvant and locally unresectable pancreas cancer series (EBRT ± IOERT) to demonstrate the justification of continuing to utilize chemo- irradiation as a component of treatment. The resultant improvements in local control with combined modality treatment, however, achieve only minimal improvements in survival in view of the high incidence of abdominal relapse (liver and peritoneal). Further improvement in survival may necessitate regional approaches for chemotherapy or may await advances in gene therapy. For locally unresectable and resected but residual bile duct malignancies, chemoirradiation appears to enhance tumor control and survival. Dose intensification of both modalities may be useful in improving disease control and survival. After chemoirradiation, the addition of liver transplant, in carefully selected patients who are unresectable with standard resection, may further enhance disease control and survival over what would be expected with either approach in isolation.

AB - For resected and unresectable pancreas cancers, data will be summarized from both adjuvant and locally unresectable pancreas cancer series (EBRT ± IOERT) to demonstrate the justification of continuing to utilize chemo- irradiation as a component of treatment. The resultant improvements in local control with combined modality treatment, however, achieve only minimal improvements in survival in view of the high incidence of abdominal relapse (liver and peritoneal). Further improvement in survival may necessitate regional approaches for chemotherapy or may await advances in gene therapy. For locally unresectable and resected but residual bile duct malignancies, chemoirradiation appears to enhance tumor control and survival. Dose intensification of both modalities may be useful in improving disease control and survival. After chemoirradiation, the addition of liver transplant, in carefully selected patients who are unresectable with standard resection, may further enhance disease control and survival over what would be expected with either approach in isolation.

KW - Biliary cancer

KW - Chemo-irradiation

KW - Pancreas cancer

UR - http://www.scopus.com/inward/record.url?scp=0032807705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032807705&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -